LONDON, Jan. 30, 2025 /PRNewswire/ -- LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress in 2024, with three ...

TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...

An exciting opportunity has arisen to join a national research programme with the aim of speeding up the diagnosis and treatment of rare respiratory diseases. The LifeArc Centre for Rare Respiratory ...

TORONTO, Jan. 27, 2025 /CNW/ - Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic ...

About the Cystic Fibrosis Trust Cystic Fibrosis Trust is the only UK-wide charity dedicated to uniting for a life unlimited for everyone affected by cystic fibrosis. The Trust funds cutting edge ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is paving the way for improving participation by trial participants who are traditionally underrepresented in Alzheimer’s clinical research, with an ...

Following the launch of LifeArc’s £100 million programme, Chronic Respiratory Infection Translational Challenge (CRI TC) – for the acceleration of the development of new clinical solutions to ...

Self-funded, non-profit medical research organisation and charity LifeArc has announced today that it is to launch the Rare Disease Translational Challenge, which will invest over £100 million by ...